Docetaxel (UGI)

Indication
Second-line treatment of locally advanced and metastatic oesophago-gastric adenocarcinoma refractory to treatment with platinum and fluoropyrimidines

ICD-10 codes
Codes with prefix C15 or C16

Regimen details

Day	Drug	Dose	Route
1	Docetaxel	75mg/m^2	IV infusion

Cycle frequency
21 days

Number of cycles
Up to 6 cycles

Administration
Docetaxel is administered as an IV infusion in 250mL or 500mL (concentration dependent) PVC free sodium chloride 0.9% over 60 minutes.

Patients should be observed closely for hypersensitivity reactions, particularly during the first and second infusions.

Hypersensitivity reactions may occur within a few minutes following the initiation of the infusion of docetaxel and therefore facilities for the treatment of hypotension and bronchospasm must be available.

If hypersensitivity reactions occur, minor symptoms such as flushing or localised cutaneous reactions do not require discontinuation of therapy. The infusion may be temporarily interrupted and when symptoms improve re-started at a slower infusion rate. Severe reactions, such as hypotension, bronchospasm or generalised rash/erythema require immediate discontinuation of docetaxel and appropriate therapy.

Patients who have developed severe hypersensitivity reactions should not be re-challenged with docetaxel.

Pre-medication
Dexamethasone 8 mg BD (morning and lunchtime) for 3 days starting 24 hours prior to chemotherapy. (Note: Patients must receive 3 doses of dexamethasone prior to treatment).
In the case where 3 doses have not been taken, dexamethasone 16-20mg IV should be administered 30-60 minutes prior to chemotherapy and the remaining 3 oral doses should be taken as normal.

Emetogenicity
This regimen has mild - moderate emetic potential

Additional supportive medication

Mouthwashes as per local policy
H_2 antagonist or proton-pump inhibitor if required
Loperamide if required.
Scalp cooling may be offered.

Extravasation

Docetaxel is an exfoliant (Group 4)

Investigations – pre first cycle

Investigation	**Validity period** (or as per local practice)
FBC	14 days
U+E (including creatinine)	14 days
LFTs	14 days

Investigations – pre subsequent cycles

Investigation	**Validity period** (or as per local practice)
FBC	96 hours
U+E (including creatinine)	7 days
LFTs	7 days

Standard limits for administration to go ahead

If blood results not within range, authorisation to administer **must** be given by prescriber/ consultant

Investigation	**Limit**
Neutrophils	≥ 1.5 x 10^9/L
Platelets	≥ 100 x 10^9/L
Bilirubin	≤ ULN
AST/ALT	≤ 1.5 x ULN
Alkaline Phosphatase	≤ 2.5 x ULN

Dose modifications

- ### Haematological toxicity

If neutrophils <1.5 x 10^9/L and/or platelets <100 x 10^9/L delay 1 week or until recovery.

If febrile neutropenia or neutrophils < 0.5 x 10^9/L for more than 1 week reduce dose to 60mg/m^2 for all subsequent cycles.

If platelets <50 x 10^9/L consider dose reduction to 60mg/m^2 after recovery (discuss with consultant)

- ### Renal impairment

There is no data available on the use of docetaxel in severe renal impairment. No modifications required.

- ### Hepatic impairment

AST/ALT (x ULN)		**Alkaline phosphatase*** (x ULN)	**Docetaxel dose**
≤ 1.5	and	< 2.5	100%
> 1.5 – 3.5	or	≥ 2.5- 6	75%
> 3.5	or	≥ 6	Discuss with consultant

*unless due to bone metastases only.
If bilirubin > 1.0 x ULN withhold dose (or consultant decision to treat)

- **Other toxicities**

Grade 3 cutaneous reactions – once recovered reduce dose to 60mg/m^2. If symptoms return, discontinue treatment.

Grade 2 neuropathy - once recovered reduce dose to 60mg/m^2. If symptoms return, discontinue treatment.

Grade 3 or 4 neuropathy – discontinue treatment permanently.

Any other grade 3 or 4 toxicity - discuss with consultant.

Adverse effects - for full details consult product literature/ reference texts

- **Serious side effects**

Secondary malignancy
Myelosuppression
Infusion related reactions
Anaphylaxis
Interstitial pneumonitis
Teratogenicity
Infertility
Cardiotoxicity
Peripheral neuropathy

- **Frequently occurring side effects**

Diarrhoea
Constipation
Fatigue
Nausea and vomiting
Myelosuppression
Stomatitis and mucositis
Arthralgia and myalgia

- **Other side effects**

Alopecia
Fluid retention
Deranged liver function
Phlebitis
Skin toxicity
Nail changes

Significant drug interactions – for full details consult product literature/ reference texts

CYP3A4 Enzyme inducers/inhibitors: in vitro studies suggest that CYP3A4 inhibitors (such as ketoconazole, ritonavir, clarithromycin and erythromycin) may raise docetaxel levels, whereas CYP3A4 inducers (such as rifampicin and barbiturates) may reduce docetaxel levels.

Additional comments

Nil

References

- Summary of Product Characteristics Docetaxel (Hospira) accessed on 6 April 2023 via www.medicines.org.uk
- Ford, H E R *et al*. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open label, phase 3 randomised controlled trial. Lancet Oncol 2014; 15:78-86

Written/reviewed by: Dr S Falk (Consultant Oncologist, UHBW NHS Trust)

Checked by: Kate Gregory (Lead Pharmacist for SACT Protocols, SWAG Cancer Alliance)

Authorised by: Dr J Braybrooke (Consultant Oncologist, UHBW NHS Trust and SWAG Cancer Alliance)

Date: April 2023